NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 1069L 
Neuropharm Group PLC 
30 April 2010 
 

 
+------------------------------------+------------------------------+ 
| For immediate release              |                30 April 2010 | 
+------------------------------------+------------------------------+ 
 
 
 
 
                              Neuropharm Group plc 
                        ("Neuropharm" or the "Company") 
 
                                 Issue of Equity 
 
 
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on 
neurodevelopmental disorders, announces the issue of 1,200,000 new ordinary 
shares of 10p each in the Company ("Ordinary Shares") following the exercise of 
options granted to Professor Eric Hollander and Professor Mark Smith in March 
2006. As a result, the Company's issued share capital now consists of 32,736,697 
ordinary shares of 10p each, with one voting right per share. The Company holds 
no ordinary shares in Treasury, therefore, the total number of voting rights in 
the Company is 32,736,697. 
 
 
 
 
For further information please contact: 
 
+----------------------------------------+----------------+ 
| Neuropharm                             | + 44 (0) 1372  | 
|                                        | 371 171        | 
+----------------------------------------+----------------+ 
| Robert Mansfield, Chief Executive      |                | 
| Officer                                |                | 
| Graham Yeatman, Chief Financial        |                | 
| Officer                                |                | 
+----------------------------------------+----------------+ 
|                                        |                | 
+----------------------------------------+----------------+ 
| Piper Jaffray Ltd.                     | + 44 (0) 20    | 
|                                        | 3142 8700      | 
+----------------------------------------+----------------+ 
| Neil Mackison, Rupert Winckler         |                | 
+----------------------------------------+----------------+ 
|                                        |                | 
+----------------------------------------+----------------+ 
| Buchanan Communications                | + 44 (0) 20    | 
|                                        | 7466 5000      | 
+----------------------------------------+----------------+ 
| Mark Court, Catherine Breen            |                | 
+----------------------------------------+----------------+ 
 
Notes to Editors: 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 IOEZBLBXBZFXBBZ 
 

Neuropharm (LSE:NPH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Neuropharm (LSE:NPH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024